Observational studyBMJ open2017
Impact of health insurance coverage for
Observational study in BMJ open, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- The cure rate of 10-day bismuth-containing quadruple therapy for Helicobacter pylori eradication is equivalent to 14-day: a systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Prevalence ofFrontiers in oncology · 2022Pooled it
- Diagnostic performance of magnifying endoscopy with third-generation narrow-band imaging for early gastric cancer: post hoc analysis of a randomized trial (3G detection trial).Journal of gastroenterology · 2026Trial
- Trends inThe Lancet regional health. Western Pacific · 2026Article
- Influence of Helicobacter pylori eradication blister-pack handling on outpatient AWaRe access share: a Japanese community pharmacy-based sensitivity analysis.Journal of pharmaceutical health care and sciences · 2026Article
- Early population-level impact of Helicobacter pylori eradication on gastric cancer mortality in Japan: a counterfactual analysis of short-term divergence.Population health metrics · 2026Article
- Spatial transcriptomic analysis of foveolar-type gastric adenoma with raspberry-like appearance.Virchows Archiv : an international journal of pathology · 2026Article
- Clinical Evaluation of a Stool-Based Molecular Point-of-Care Test Kit for Noninvasive Detection of Helicobacter pylori Infection and Clarithromycin Resistance.Canadian journal of gastroenterology & hepatology · 2026Article
- Forecasting age-standardized incidence rates of gastric cancer from 1990-2050 in Japan according to H. pylori prevalence and eradication scenarios.Journal of gastroenterology · 2025Article
- Gastric cancer risk after Helicobacter pylori eradication in gastritis and peptic ulcer: a retrospective cohort study in Japan.BMC gastroenterology · 2025Article
- Helicobacter pylori eradication and gastric cancer prevention in a pooled analysis of large-scale cohort studies in Japan.Scientific reports · 2025Article
- Co-occurrence patterns of esophageal and stomach cancer across 204 countries and territories: a spatial correspondence and systematic analysis.Frontiers in oncology · 2025Article
- Addressing the global challenge ofGut microbes reports · 2025Article
- Challenges and future directions of gastric cancer prevention in Iran: Perspectives of the key stakeholders.Journal of education and health promotion · 2025Article
- Validity of Self-reported Helicobacter pylori Eradication Treatment From Questionnaire and Interview Surveys of the JPHC-NEXT Study: Comparison With Prescription History From Insurance Claims Data.Journal of epidemiology · 2024Article
- National trends in hospitalizations for gastrointestinal bleeding in Japan.Journal of clinical biochemistry and nutrition · 2024Article
- Time trend analysis of rare cancer incidence 2011-2018: Nationwide population-based cancer registries in Japan.Cancer science · 2024Article
- Efficacy and Tolerability of 14-Day Tegoprazan- versus Rabeprazole-Based Triple Therapy for Eradication ofGut and liver · 2023Article
- Long-term Response of Helicobacter pylori Antibody Titer After Eradication Treatment in Middle-aged Japanese: JPHC-NEXT Study.Journal of epidemiology · 2023Article
- Real-world outcomes associated with vonoprazan-basedTherapeutic advances in gastroenterology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo explore the prevalence of
methodsIn this retrospective observational study and simulation study based on health insurance claims data, product sales data and relevant studies, individuals who received triple therapy (amoxicillin, clarithromycin, proton-pump inhibitors or potassium-competitive acid blockers) were defined as the first-time patients for
resultsThe numbers of patients first received eradication therapy were 81 119 and 170 993 from two databases. The nationwide estimated number of patients successfully eradicated was approximately 650 000 per year between 2001 and 2012, whereas it rapidly rose to 1 380-000 per year in 2013. The estimated prevalence of infection in 2050 is 5%, this rate was estimated to be 28% and 22% if the policy changes had not occurred in 2000 and 2013, respectively.
conclusionsThe impact of policy changes for
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.